|Bid||83.95 x 800|
|Ask||83.97 x 800|
|Day's Range||83.61 - 85.14|
|52 Week Range||56.91 - 88.71|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||77.75|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||0.80 (0.95%)|
|1y Target Est||90.40|
Could CONMED Corporation (NASDAQ:CNMD) be an attractive dividend share to own for the long haul? Investors are often...
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
CONMED Corporation (CNMD) today announced that it will report financial results for the second quarter of 2019 after the market close on Wednesday, July 31, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and refer to the passcode 6992059.
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
Today we are going to look at CONMED Corporation (NASDAQ:CNMD) to see whether it might be an attractive investment...
CONMED Corporation (CNMD) today announced that independent director, Dirk M. Kuyper, has submitted a notice of resignation, which will take effect on August 1, 2019. “Dirk has been a highly valued voice in the board room for the past six years, and we are grateful for his service to CONMED,” commented Mark Tryniski, Chair of CONMED’s Board of Directors, “Dirk has provided truly valuable insights and strategic direction to management throughout his tenure on the Board, and, on behalf of the entire Board of Directors and our leadership team, I thank Dirk for his important contributions to CONMED’s success.
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Conmed Corp NASDAQ/NGS:CNMDView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for CNMD with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 12. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CNMD had net inflows of $1.22 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.